The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence
Wilms Tumor, Relapse, Death
About this trial
This is an interventional diagnostic trial for Wilms Tumor
Eligibility Criteria
Inclusion Criteria:
- All children presented with Wilms' tumour at the Urology and Nephrology Center, Mansoura University, Mansoura, Egypt from 2000 to 2014.
Exclusion Criteria:
- Preoperative chemotherapy (due to areas of necrosis and haemorrhage hindering immunohistochemical staining).
- Patients with incomplete follow-up data.
Sites / Locations
- Mansoura Urology and Nephrology Center. Faculty of Medicine, Mansoura UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
P53 IHC
Ki67 IHC
Cyclin A IHC
P53 staining density and intensity will be calculated. To assess P53 density in a semiquantitative way, a score of 0 will be given assigned if less than 5% of tumour cells expressed p53, 1 if 5% to 50% expressed p53 and 2 if more than 50% stained positive for p53. To evaluate P53 intensity, a score of 0 means weak or absent staining, 1 refers to the intermediate intensity and 2 stands for strong intensity.
Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
Regarding Cyclin A, a standard peroxidase-conjugated streptavidin-biotin labelling was used for visualization, with 3,3 diaminobenzidine as chromogen. Level of cyclin A expression will be classified as absent (-), focal (+), moderate (++) diffuse (+++).